Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Japanese encephalitis vaccine · 1 trial · 2 indications
Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer \<10 1/dil and post-vaccination titer ≥ 10 1/dil, or participants with pre-vaccination titer ≥ 10 1/dil and 4-fold increase from pre- to post-vaccination.
| Arm | Type | Description |
|---|---|---|
| JE-CV GPO MBP (Lot 1) | EXPERIMENTAL | Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1. |
| JE-CV GPO MBP (Lot 2) | EXPERIMENTAL | Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2. |
| JE-CV GPO MBP (Lot 3) | EXPERIMENTAL | Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3. |
| JE-CV WRAIR (Group 4) | ACTIVE_COMPARATOR | Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR) |
| Hepatitis A (Group 5) | SHAM_COMPARATOR | Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine |
| Name | Type | Description |
|---|---|---|
| Japanese encephalitis vaccine | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Japanese encephalitis vaccine (Acambis) | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Hepatitis A vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Aged 12 to 18 months on the day of inclusion. * In good general health, without significant medical history. * Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by l...
Japanese encephalitis vaccine is used for the prevention of Japanese encephalitis, a viral infection of the brain transmitted by mosquitoes. It is being studied in toddlers in Thailand and the Philippines, where the disease is endemic. The vaccine is designed to protect against the Japanese encephalitis virus, which can cause severe neurological disease.
Japanese encephalitis vaccine is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the vaccine's safety and efficacy in preventing Japanese encephalitis in pediatric populations.
Japanese encephalitis vaccine is in Phase 3 clinical development. This phase involves large-scale studies to confirm the vaccine's efficacy and monitor for adverse reactions in a larger population. The vaccine is investigational and has not yet been approved for public use.
Japanese encephalitis vaccine has one completed Phase 3 clinical trial, identified as NCT00735644. This study, titled 'Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines,' enrolled 1,200 participants aged 12 months and older. The trial was active-controlled and conducted in the Philippines and Thailand.
Japanese encephalitis vaccine is associated with the ChimeriVax™ technology, as indicated by the clinical trial title. The vaccine uses a chimeric virus platform, which combines genes from different viruses to create a safe and effective vaccine. This technology is part of Sanofi's vaccine development approach.